Efficacy
DISEASE, MINIMAL RESIDUAL DISEASE
Overall, 14 patients had a bone marrow assessment and were assessed for efficacy. An objective response was reported in three patients (one patient in each of cohorts 4, 5 and 6), with a complete response in two patients and a complete response with incomplete recovery of haematological counts in one patient. Refractory disease and progressive disease were reported in four and seven patients, respectively. One patient from cohort 5 achieved a negative minimal residual disease status in the blood at cycle 2 and cycle 3.At the time of data cut-off, 16 patients had died; median overall survival was 53 days (95% Cl: 35.0, 124.0) and the median 6-month overall survival rate was 17.6% (95% Cl: 4.3%, 38.3%).